Vaxart (NASDAQ:VXRT) Shares Pass Below 200 Day Moving Average - Should You Sell?

Key Points

• Vaxart's share price has fallen below its 200-day moving average, trading as low as $0.35, with a current price of $0.39.
• Despite recent struggles, Vaxart has received a "hold" rating from Wall Street Zen and maintains an average price target of $2.00 from analysts.
• Several institutional investors have increased their stakes in Vaxart, with notable increases from Bank of America Corp and Graham Capital Management, indicating potential investor confidence.

Vaxart, Inc. (NASDAQ:VXRT - Get Free Report)'s share price passed below its two hundred day moving average during trading on Thursday . The stock has a two hundred day moving average of $0.43 and traded as low as $0.35. Vaxart shares last traded at $0.39, with a volume of 904,595 shares changing hands.

Analyst Upgrades and Downgrades

Separately, Wall Street Zen upgraded shares of Vaxart to a "hold" rating in a research report on Thursday, May 22nd. One investment analyst has rated the stock with a Buy rating, According to MarketBeat, Vaxart presently has a consensus rating of "Buy" and an average price target of $2.00.

Vaxart Trading Up 2.6%

The company's 50 day moving average price is $0.38 and its two-hundred day moving average price is $0.43. The firm has a market cap of $89.26 million, a PE ratio of -1.44 and a beta of 1.33.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently modified their holdings of VXRT. Bank of America Corp DE boosted its stake in shares of Vaxart by 10.8% during the 4th quarter. Bank of America Corp DE now owns 184,447 shares of the biotechnology company's stock worth $122,000 after acquiring an additional 17,942 shares during the last quarter. Graham Capital Management L.P. raised its position in shares of Vaxart by 155.8% during the 4th quarter. Graham Capital Management L.P. now owns 53,331 shares of the biotechnology company's stock valued at $35,000 after purchasing an additional 32,482 shares during the period. Squarepoint Ops LLC raised its position in shares of Vaxart by 95.0% during the 4th quarter. Squarepoint Ops LLC now owns 516,798 shares of the biotechnology company's stock valued at $342,000 after purchasing an additional 251,789 shares during the period. Invesco Ltd. raised its position in shares of Vaxart by 93.1% during the 1st quarter. Invesco Ltd. now owns 146,366 shares of the biotechnology company's stock valued at $60,000 after purchasing an additional 70,568 shares during the period. Finally, Virtu Financial LLC bought a new stake in shares of Vaxart during the 1st quarter valued at $56,000. Hedge funds and other institutional investors own 18.05% of the company's stock.

About Vaxart

Vaxart, Inc, a clinical-stage biotechnology company, discovers and develops oral recombinant protein vaccines based on its proprietary oral vaccine platform. The company's product pipeline includes norovirus vaccine, a bivalent oral tablet vaccine in Phase 2 clinical trial for the GI.1 and GII.4 norovirus strains; coronavirus vaccine, which is in Phase 2 clinical trial, for the treatment of SARS-CoV-2 infection; seasonal influenza vaccine, which is in Phase 2 clinical trial, to treat H1 influenza infection; and human papillomavirus therapeutic vaccine, which is in preclinical stage, that targets HPV-16 and HPV-18 for cervical cancers and precancerous cervical lesions.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.